OncoSil Medical Limited

OSL

AU000000OSL3

Pharmaceuticals

Market Closed - Australian S.E. Other stock markets 11:08:31 01/07/2024 am IST			5-day change	1st Jan Change
0.005 ^AUD	+25.00%		0.00%	-44.44%

11/06	OncoSil Medical Treats Fifth Pancreatic Cancer Patient with Proprietary Device	MT
03/06	Oncosil Medical Treats 200th Pancreatic Cancer Patient with Proprietary Device	MT

Oncosil Medical Limited Appoints Chris Roberts as Independent Non-Executive Director

January 21, 2016 at 03:19 am IST

Oncosil Medical Limited announced the appointment of Dr. Chris Roberts as an Independent Non-Executive Director of the Company, with immediate effect. He was Chief Executive Officer/President of Cochlear Limited from February 2004 to August 2015.

Latest news about OncoSil Medical Limited

OncoSil Medical Treats Fifth Pancreatic Cancer Patient with Proprietary Device	11/06	MT
Oncosil Medical Treats 200th Pancreatic Cancer Patient with Proprietary Device	03/06	MT
Oncosil Medical Enters Distribution Agreement with Abdulla Fouad Group for Saudi Arabia	23/05	MT
OncoSil Medical Raises AU$5.3 Million under Entitlement Offer	02/05	MT
OncoSil Medical Treats Two More Patients in Netherlands in Pancreatic Cancer Trial	18/04	MT
OncoSil Medical Treats First Commercial Patient in Turkey with Implantable Pancreatic Cancer Device	16/04	MT
OncoSil Medical Treats First UK Patient for Pancreatic Cancer Study	12/04	MT
OncoSil Medical Obtains Device Reimbursement Approval in UK	09/04	MT
First Austria-Based Patients Treated Using OncoSil Pancreatic Cancer Device	05/04	MT
Oncosil Medical Issues Non-Renounceable Entitlement Offer Prospectus	25/03	MT
Oncosil Medical to Raise Over AU$7 Million via Placement, Entitlement Offer	20/03	MT
OncoSil Medical Limited Reports Earnings Results for the Half Year Ended December 31, 2023	28/02	CI
Australian Shares End Eight-Day Winning Streak as Early US Fed Rate Cut Hopes Fade	01/02	MT
OncoSil Device Included in German Funding Program Negotiations; Shares Jump 14%	01/02	MT
OncoSil Strikes Exclusive Distribution Deal For Turkish Market; Shares Jump 14%	01/02	MT
OncoSil Medical Receives AU$1.1 Million R&D Tax Rebate	15/12	MT
First Patient Treated in OncoSil Medical's Pancreatic Cancer Drug Trial	29/11	MT
Oncosil Medical Limited Elects Gabrielle Liberatore as Director	29/11	CI
Australian Shares Rise on Expectations of Easing October CPI	24/11	MT
OncoSil Medical Secures Insurer Clearance for Pancreatic Cancer Device in Israel	24/11	MT
OncoSil Medical Limited Announces Retirement of Brian Leedman from the Board	18/23/18	CI
OncoSil Medical Limited Reports Earnings Results for the Full Year Ended June 30, 2023	31/23/31	CI
Oncosil Medical Limited Announces Change of Principal Place of Business	16/23/16	CI
OncoSil Medical Limited Appoints Doug Cubbin as Director	10/23/10	CI
Oncosil Medical Appoints Incoming Chair	07/23/07	MT

Chart OncoSil Medical Limited

Duration

Period

More charts

Company Profile

OncoSil Medical Ltd is an Australia-based medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer (LAPC). The Company is focused on the development and commercialization of its lead product candidate, the OncoSil localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma. The Company has developed a cancer treatment device, the OncoSil brachytherapy device, which is a critical component of a brachytherapy treatment for locally advanced unresectable pancreatic cancer. The OncoSil device delivers a targeted intratumoral placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. The OncoSil device has received a device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy.

Sector

Pharmaceuticals

Calendar

22/08/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ONCOSIL MEDICAL LIMITED	-44.44%	88.93L
ELI LILLY AND COMPANY	+56.86%	82TCr
NOVO NORDISK A/S	+43.90%	64TCr
JOHNSON & JOHNSON	-6.57%	35TCr
MERCK & CO., INC.	+17.32%	31TCr
ABBVIE INC.	+9.94%	30TCr
ASTRAZENECA PLC	+16.08%	24TCr
ROCHE HOLDING AG	+2.29%	22TCr
NOVARTIS AG	+13.96%	22TCr
AMGEN INC.	+7.98%	17TCr

Other Pharmaceuticals